6-chloro-N-[1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]pyrazol-3-yl]-2-oxo-1H-quinoline-4-carboxamide
C20H21ClN6O3 — CID 166210561
Data last refreshed: (MolForge compound catalog, from PubChem)
About 6-chloro-N-[1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]pyrazol-3-yl]-2-oxo-1H-quinoline-4-carboxamide
6-chloro-N-[1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]pyrazol-3-yl]-2-oxo-1H-quinoline-4-carboxamide (PubChem CID 166210561) has the molecular formula C20H21ClN6O3 and a molecular weight of 428.88 g/mol. Its IUPAC name is 6-chloro-N-[1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]pyrazol-3-yl]-2-oxo-1H-quinoline-4-carboxamide.
Molecular Properties
| Compound Name | 6-chloro-N-[1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]pyrazol-3-yl]-2-oxo-1H-quinoline-4-carboxamide |
|---|---|
| PubChem CID | 166210561 |
| Molecular Formula | C20H21ClN6O3 |
| Molecular Weight | 428.88 g/mol |
| Exact Mass | 428.14 |
| IUPAC Name | 6-chloro-N-[1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]pyrazol-3-yl]-2-oxo-1H-quinoline-4-carboxamide |
| SMILES | CN1CCN(C(=O)Cn2ccc(NC(=O)c3cc(=O)[nH]c4ccc(Cl)cc34)n2)CC1 |
| InChI | InChI=1S/C20H21ClN6O3/c1-25-6-8-26(9-7-25)19(29)12-27-5-4-17(24-27)23-20(30)15-11-18(28)22-16-3-2-13(21)10-14(15)16/h2-5,10-11H,6-9,12H2,1H3,(H,22,28)(H,23,24,30) |
| InChIKey | XTGUKFLZVCYDDZ-UHFFFAOYSA-N |
| XLogP | 1.40 |
| TPSA | 103.33 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 428.88 |
| LogP ≤ 5 | 1.40 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 166210561 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.